Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 14/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.35 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617264 | 0.92 | FAAH (0.43) | TNFGAACTNNB1FAAHTPH1 | |
| SCHEMBL4326967 | 0.72 | TLR8 (0.32) | TLR7 | |
| SCHEMBL4324672 | 0.72 | TLR8 (0.34) | TLR7 | |
| Trifluoroacetic Acid SCHEMBL5030373 | 0.70 | TLR8 (0.35) | TLR7 | |
| SCHEMBL483380 | 0.69 | TLR7 (0.61) | TLR7 | |
| SCHEMBL5030389 | 0.67 | TLR8 (0.33) | TLR7 | |
| SCHEMBL4004026 | 0.66 | TLR7 (0.62) | TLR7 | |
| SCHEMBL5617263 | 0.65 | TNF (0.45) | TNFGAACTNNB1FAAH | |
| SCHEMBL4158992 | 0.65 | TNF (0.48) | TNFGAACTNNB1FAAHTLR7 | |
| SCHEMBL5617062 | 0.64 | TLR7 (0.43) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697873-B2 | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | TNF 77/4885GAA 2214/4885CTNNB1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.